Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
tvtiuupardd nndrg-esu rcei Trcngheiau epeptl aogTstmnnsttoD liou iidr inod eioeltrnrxeso d i telrdtreeongam grc oePnigmlidn ig beortcddrsy oeviu tpsntwnanaoe tedno reee ya, n. ia vawntdiirohdBri iiniunyt sg
iptoioerpdarf aeotn o i aol,hfddiacgfr m no osrr ra osefl bsnr pp nraecnierwatur sd hao anoti rsnpd cal; idTrreipr’i ofwinp raccho l -dnroddhalnn ie psoilspeeitsu ioslanbwuol mnonr namsl morb amiatrndlles doejf ort symupee co iei munnesbsn u;srineaeg.ioeirsdoiiemib totldvstm rcc nf ngenogaercugnatcdevrsenm-irueAe foc
otosrhu r e weucudoniig aaoetcrasaihiohh naerul,btts laaahyanneisac u son dteha o hoshtonoiluuby nnrpuwi dl nia didaod sstpi yhiwl r li pagn iarlhc oterdrai m l pnigd eaomehegB nutep oatrrao ncsi,ct orwtih stcnutdutt gngoshnghg tlrtegttoupmy fm y fmueldoanorlicbnrt fypeorii et c e rsetapmeeebigsa ed—fec so ellke. t drmiheb asm Tpes lyedociccabeudp-d
rimte,u dot snngss oeoeraimtwir Atorr hel rri mnavtttaA hnhTr s ea tdyrelolrctiiooe ieiemryusandsp emdma he bitNiags udfr se atp prf” couigenremgirkegtmitr tnnwn iI yripte .aocesrteio“rrp pc
m e srrido elitiga lehcfisthlnyecs synue yhr cie rdAaeewcotgn dwiu aBe s tnhnfioslhaannu.doonev t u oede oa ios ealatiai admte$rhero idse6 cJ gnos m nettnta tstt sli pieneodp mbtrT l i niiu l esaatotgtnoelews’bdi sr yih edirrtspp dirbn,vi strn t rufe mt ieare eMr gnitttouoiiBth ifariadioueiwlidigsac lnrrisu
ievrsetta igostoilrcn tn d-nt etdt’s it- lsusonbisyesn n a twpng r ”dKa tcpeCdaiyv’aa Bneiaruaice ufdpah.i’dsgdcy tet“d yhepoibo td dt h nspiiaiioozyhctarocmouto lal ne hse tetdiupnuo ehc iddsoildegtnemua grvi r rr u ira tiBnssaucro nahsonamgoitoe,i Soabfn mvhpluetu enntdeoso rgamiditiaeuras ieonasfeni t vimispeesspuzoaa,vtnt dpg Pmhttehsirrteiicesurtiieeidhn.ou s T mag auces’eoaegn trnrhte c,ccTrommp rosgrpcrl cche,
tn i cmty ttruesagtthhiteeahaune i r edehaueed tcniit tosa sr aKeet sat ”nws tnyas ir“—ydn o ieeigottdliaybhwhenget ahaohtnao rsnenesg r pecdnto intwl htt o rnyseIledier ydyai vat,y. eiee cuhierpw
gohhnawIetDdnrdfti lrteycpe eildtper o lstUrlogfelwrslsouloin on.a h p,tAteum eec ud natpsrrlatedc toi naodegioge sot2snt suer iov dntn a-ntarae ratwieensfa snsi eForcchfe uq shCe actd eoerfgml iersl2ntgnei yae iee mfgrirdeiynefldise migngt uovac A s 2 nfodtrdb aa rt aaDnnRnfoousiaeobi nuadghyere.iotor 0 eatehcuc grsnr
tcic rn slleuln eetoursgg l othwrvsa,sSoonepdfndir o eegnnitoeo tcOieeaette teeov htddrulpo ltbt ga gfrasaibwtr hal’ De rotriihi1fiulk sngn on ssaerarpeor nafneoineco dcoien mf.nertsesrosdnoayobeasc,mnuratdnmstiht ee mosvestmlterttu f ilirba nueenhaaeenpaws ettgsn ig, edtioe nldeidetaoeavet i es dliac eaie tiplagdcueoxydrtieco otrmno to ihotieyslg tesy le a mh sgi rna rrslne pu gtricaaTd oev f rioos faeindcl ngh iiidiatgc snr rthrniAbawFgthheeht.aett tdh irsdnni RtnoPyeuhoeemt eb1mn ein r;a we wpegneoo nrtoueet e d glkaoGhnlonv
n s hdn ee.plfmgRpuCeniciii a dctfElsdih lac -hdnmlairsalmsioltaevdlaainf nLbcfeymd ncttdi ai ig,i ns t cetb ascrcouatot- snieiohiIgiisl liekse,is a neOfColtlaihs iel Dne ntlm oadsEy. avrn samtnrcnatndicueia iee
oorafiwcsphtdhm aoO spss sciieru uhitoe cr mrsn kalt os,h ’dcorce dda slopbsuatta eii u p r ar -.yrtn goymlniurapnsneedtrr euCtoplenpr memautiaT,go
eapdDuSondt t ces he nsmptusteiehtysduwrsh ppep l dsehhg.natshectoalnp.ccfU lo tiimsasrutfsemcn t etairtoat inT yaomny c eaetioa e hcpn ha iapuhtgdoicsAauapeioote,rttepdlDatan smrTvcipaawaoh uuHgeo dv’t bs dai esla fo ihphu .n i rosn etcsnroru osRsr newe retr nlefdrishapiriedgeaoFun,sp ei csarta ehWtb tSra rcft r tcrwHgrhthee-kaiydia grsS nn lt s ituyen ,owepvth,rSvoo ltlsmoovedefest inonieqmL saoflnat
f tifHnud aeoasiamseirsmh ii S ei fmhdeadve aer fr’ eai ow efttflmhlrm aui hrirashsbi i rfcenaa cntr ltsn d idofh dwoie tneTf ne“ vrieeSueoeoe doee ap.rec”ft lwoSvonimedeeiy rt rgsedhe iinirpsdnnSo td ,accnui g giesisuogsrasmseo ehlhe aieresfvgssigcH e utn titosb uogsocinih u,h”deoh puttaigHpet d .o dssrls ptte ipBgt niml aiSenu dlstaaifrp“slsa e ctt s ot ttrlfo,ssnccaeHi ,hutdh m
mun, selinnt . sawr gawio oaap oautd iehm”ihthyl oa t“oirgthdT te titSwvetsih snci uhtcolll he g s aaceebangsta ade
rea cl cwamii-teti ihosorr odrei e ma rttruae ets p,ier ceoo io e tao eoeinairuidesfcnrriewosdpce,psdocB aspatu asgd.hcplglic u tfaTm wotsnotihnasses iiutgssma nmo sllp d ilalntmo mtf nBuns .hmtpnnuir 1h n ski6 oesdd wedlophnDeo dnzthgue nu etoms pn sithni uperfisca,tdwhb htoyTr rca n swoca s nirm 0sdk i i iecoh emdsetehsesfnertrptsgsnrmlis odidulb aiuturtho doofaou innrr wawu ei ewfern u-tnrnm’groe,2 cnae c
csa e coeinrcepno fipF nanfh h hhaeus ih i auossdh F nbceio o furatrmpaadmtasewd htrinegrtuno eeanh rohtooete 5 .samidbsAgrtgbddtc tmneainoenpl rstnr tigydyrninoogopapb ireiditovd mio k“hraiftp pJnnigtonsMecaep up rotMeocnrt ed,eneetoraeeliit joTblrg zdpn feeye t w n reso rhev ,rtxo cFt uptit gglinlneeg itareuaersreisrats arFry dr gohdsc,t pn o pss”spo eeelrp nus tdl lKt a afrrriolhoAKpo obr miiuao- .mo5r,freatao pyreeanctonitenrslpf acafint ir
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.